

COVID-19 Pneumonia

**A study to find out if a new medicine (either astegolimab or efmarodocokin alfa) was safe and effective in patients with severe COVID-19 pneumonia**

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

**Trial Status**  
Completed

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT04386616 GA42469

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

**NCT04386616 GA42469**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

This clinical trial was done to study two new medicines called, astegolimab” and “efmarodocokin alfa”, for the treatment of patients with severe COVID-19 pneumonia. This study was done to find out if either medicine was effective and safe for treating patients with severe COVID-19 pneumonia in comparison to placebo treatments. There were 396 patients who took part in this study at 54 study centers in 4 countries.